• Explore /
  • Poster
  • / Sintilimab for relapsed/refractory classical Hodgkin’s lymphoma: Extended follow-up on the multicenter, single-arm phase II ORIENT-1 study.

Sintilimab for relapsed/refractory classical Hodgkin’s lymphoma: Extended follow-up on the multicenter, single-arm phase II ORIENT-1 study.

Abstract Poster

Authors

null

Hang Su

The 307th Hospital of Military Chinese People's Liberation Army, Beijing, China

Hang Su , Yongping Song , Wenqi Jiang , Xiuhua Sun , Wenbin Qian , Wei Zhang , Yuhuan Gao , Zhengming Jin , Jianfeng Zhou , Chuan Jin , Liqun Zou , Lugui Qiu , Wei Li , Jianmin Yang , Ming Hou , Shan Zeng , Peng Liu , Yuankai Shi , Hui Zhou , Shuyan Wang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Hodgkin Lymphoma

Clinical Trial Registration Number

NCT03114683

Citation

J Clin Oncol 37, 2019 (suppl; abstr 7533)

DOI

10.1200/JCO.2019.37.15_suppl.7533

Abstract #

7533

Poster Bd #

287

Abstract Disclosures

Similar Posters

First Author: Hang Su

First Author: Yuankai Shi

First Author: Jiayong Liu

First Author: Yige Bao